OBJECTIVE: To investigate whether retinoid X receptor agonists act as insulin sensitizers and compare their effects with that of thiazolidinedione BRL 49653 in obese Zucker rats. DESIGN: In two independent studies, obese Zucker rats were dosed orally once daily for 14 days with one of the following treatments: LG 100268 (20 mgakg), LG 100324 (20 mgakg), BRL 49653 (3 mgakg) or vehicle. MEASUREMENTS: Daily food intake and body weight gain, blood glucose, plasma and pancreatic insulin, whole body glucose disposal (by euglycaemic ± hyperinsulinaemic clamp) and tissue glucose utilization. RESULTS: The retinoid X receptor agonists (rexinoids) LG 100268 and LG 100324 caused a reduction in the food intake of obese Zucker rats relative to controls and to rats receiving BRL 49653. The two rexinoids also produced a marked decrease in the body weight gain, whereas the growth rate of rats treated with BRL 49653 tended to increase. Both rexinoids and BRL 49653 reduced the plasma insulin concentration of fed rats.
Introduction
Recent insights into the transcriptional regulation of adipocyte differentiation have come from studies of the regulatory regions of adipocyte-speci®c genes. Characterization of important transcription factor binding sites led to the identi®cation of peroxisome proliferator-activated receptors (PPARs). 1 PPARg, an adipocyte-enriched member of the subfamily, has been shown to play a central role as a regulator of terminal adipocyte differentiation (for reviews, see Lemberger et al 1 and Mandrup and Lane 2 ) and it functions as a heterodimer with another member of the nuclear receptor subfamily, the retinoid X receptor (RXR; see Mangelsdorf and Evans 3 for a review). The thiazolidinedione insulin sensitizers are a new class of anti-hyperglycaemic agents that are believed to act via activation of PPARg nuclear receptors. 4, 5 High-af®nity binding sites for rosiglitazone (BRL 49653) in rodent and human adipocytes have been identi®ed using a radio-iodinated ligand for PPARg. 6 Thiazolidinediones improve glycaemic control by enhancing insulin action in peripheral target tissues in animal models of non-insulin dependent diabetes (NIDDM) and have proved to be effective in clinical trials for the treatment of NIDDM. 4, 5 Evidence has recently been provided that RXR ligands can also function as insulin sensitizers and can decrease hyperglycaemia, hyperinsulinaemia and hypertriglyceridaemia in obaob and dbadb mice. 7 This anti-diabetic activity can be further enhanced by combination treatment with PPARg agonists such as thiazolidinediones, which suggests that the RXR-PPARg heterodimer is a single-function unit that allows integration of two independent hormonal signalling pathways serving as a molecular target for the treatment of insulin resistance. In the present study, the insulin sensitizer activities of two RXR agonists, LG 100268 and LG 100324, were compared with that of the thiazolidinedione BRL 49653 in Zucker faafa rats.
Materials and methods

Drugs
LG 100268, LG 100324 and BRL 49653 ( Figure 1 ) were prepared at Ligand Pharmaceuticals. The compounds were supplied blinded in a dosing vehicle consisting of 0.9% carboxymethyl cellulose, 9.95% polyethylene glycol and 0.05% tween 80.
Animals and treatments
Male obese Zucker rats were purchased from two different sources: Charles River, France (experiment 1) and St George's Hospital Medical School, London (experiment 2). The rats were maintained in our animal facility for at least 2 weeks prior to the study and were fed on a rat and mouse toxicology diet (Bantin and Kingman, Hull, UK) with free access to water. They were kept at 21 AE 1 C on a 12 h:12 h light ± dark cycle. At the start of the study the rats were aged 10 ± 11 weeks.
The rats were assigned to four treatment groups and were dosed orally daily with LG 100268 (20 mgakg),
LG 100324 (20 mgakg), BRL 49653 (3 mgakg) or vehicle for 14 days. Body weight change and daily food intake were measured during the treatment period. Blood samples (from animals in the fed state) were taken from the tail on days 0, 8 and 13 for the determination of blood glucose and plasma insulin concentrations.
Euglycaemic ± hyperinsulinaemic clamp
The procedure used to perform the euglycaemic ± hyperinsulinaemic clamp was similar to that described previously. 8, 9 The rats were dosed orally at 08:00 h and then food was withdrawn for 5 h prior to the start of the clamp. After taking a blood sample from the tail for the measurement of plasma insulin, anaesthesia was induced by intraperitoneal administration of HypnormaHypnovel (2 mlakg body weight) and maintained throughout the study by further administration of anaesthesia as required. The rats were placed on a thermal blanket linked to a core temperature probe and body temperature maintained at 37 C. A small incision was made in the skin to expose the femoral vein and a stainless steel indwelling cannula inserted. A bolus of D- H]-glucose tracer (10 mCiakg body weight; Amersham International, Amersham, UK) in 0.9% sterile saline was then administered followed by a continuous infusion of D-[6-3 H]-glucose at 0.2 mCiakgamin and soluble insulin (Human Actrapid, Novo Nordisk, Bagsvaerd, Denmark) at the rate of 10 mUakgamin. The infusion started after obtaining a blood sample from the tail and the blood glucose concentration was determined within 1 min. The blood glucose concentration was then determined every 5 min and a 1.0 M D-glucose solution was infused at a variable rate to maintain the blood glucose concentration at 6 mmolal. Glucose infusion rates necessary to maintain euglycaemia were calculated over the last 60 min of the insulin infusion, when the rats were in steady state.
Estimation of individual tissue glucose utilization rates
The rate of glucose utilization for several tissues was estimated using the non-metabolizable glucose analogue 2-deoxy-D-[1-14 C]-glucose (2-DG; Amersham International, Amersham, UK) as described previously. 10 Brie¯y, 60 min after the start of the infusion of insulinaD- H]-glucose, a bolus of 2-DG (5 mCiakg) was given intravenously and blood samples for the determination of plasma 2-DG-radioactivity were obtained at 5, 10, 15, 20, 30, 45 and 60 min after bolus administration. Rats were then killed after taking a blood sample for the determination of the terminal plasma insulin concentration and gastrocnemius muscle, back muscle, diaphragm, interscapular brown adipose tissue (BAT) and pancreas were rapidly removed and frozen in liquid nitrogen. In order to estimate tissue 2-deoxy-D-[1- by ion-exchange chromatography. The tissue glucose utilization index was calculated as described previously. 11 
Analytical methods
Blood glucose was measured using hexokinasea glucose-6-phosphate dehydrogenase as a commercial kit (Sigma, Poole, UK) in a Beckman DU-7 spectrophotometer equipped with a kinetics software package. Plasma insulin concentration was measured by radioimmunoassay using a double antibody procedure (Linco Inc., supplied by Biogenesis Ltd, Cambridge, UK). Pancreatic insulin content was determined as described by Perfetti et al 12 and Martin et al 13 with modi®cation. Brie¯y, individual pancreas was homogenized in 10 vols (5 vols for the second extraction) of ice-cold 75% ethanol containing 1.0 M acetic acid and 0.1 M HCl. The homogenate was extracted overnight at 4 C and then centrifuged, and the supernatant was diluted 1:1000 with insulin radioimmunoassay (RIA) buffer. The insulin content of the whole pancreas was then determined by RIA.
Statistical analysis
Results are presented as meansAE s.e.m. Differences between groups were analysed by analysis of variance (ANOVA) followed by Dunnett's multiple comparison test.
Results
The obese Zucker faafa rats used in the present study were from two different sources (due to shortage of supply at the time when this study was carried out). Although the rats were from the same parent stock, there were obvious differences between them. The rats from Charles River had a brown coat colour instead of black and were less insulin resistant compared with rats from St George's Hospital Medical School (ie fed plasma insulin level: 4.1 AE 0.80 vs 17.5 AE 2.3 nmolal; P`0.001). We have, therefore, presented the results separately as experiment 1 (using rats from Charles River) and experiment 2 (using rats from St George's Hospital).
The effect of the treatments on daily food intake is shown in Figure 2 . Both of the rexinoids decreased daily food intake before the end of the ®rst week of treatment and this decrease became more profound during the second treatment week (6.6 g per day less in LG 100268-treated rats (P`0.01) and 4.0 g per day less in LG 100324-treated rats (P`0.05) compared with controls), whereas the mean daily food intake during the second week in the BRL 49653-treated group was increased signi®cantly (P`0.05; experiment 1). In experiment 2, both LG 100268 and LG 100324 caused a marked decrease in food intake from day 6 and this decrease was sustained for the rest of the treatment period (P`0.001). Figure 3 shows the effect of the treatments on body weight gain. Treatment for 2 weeks with LG 100268 and LG 100324 produced a numerically lower body weight in experiment 1 and a signi®cant reduction (P`0.01) in experiment 2 as compared with the control rats. In contrast, the trend in body weight gain in rats treated with BRL 49653 was numerically higher (210% and 149%) relative to the controls.
None of the treatments signi®cantly affected the fed blood glucose concentration (Figure 4 ). In experiment 1 the variation in the fed insulin concentration on day 0 was large. Thus, although the mean insulin concentration in the rats given the rexinoids was less than 20% of the corresponding mean value on day 0, the changes were not signi®cant statistically.
The animals used in experiment 2 were more hyperinsulinaemic than those in experiment 1 and both rexinoids resulted in a signi®cant reduction in the plasma insulin concentrations (P`0.01) after both 7 and 14 days of treatment (Figure 4) . 
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The effects of the treatments on the 5 h-fasted and terminal plasma insulin concentrations are shown in Figure 5 . In both experiments, both LG 100268 and LG 100324 caused a signi®cant decrease in 5 h-fasted plasma insulin concentration whereas in the BRL 49653-treated animals the plasma insulin concentration was not signi®cantly different from controls. The terminal insulin concentrations (at the end of the clamp) in experiment 1 were numerically lower in all treatment groups, with only 60% of the control value in LG 100268-treated group, although this was not signi®cant (experiment 1; Figure 5 ). The terminal insulin concentrations in experiment 2 were decreased signi®cantly by all treatments to 49%, 57% and 56% of control value in LG 100268-, LG 100324-and BRL 49653-treated groups respectively (P`0.05; experiment 2; Figure 5 ). None of the treatments had any effect on pancreatic insulin content (results not shown).
Hepatic glucose production (calculated by difference between the whole body glucose utilization rate and the glucose infusion rate) during the euglycaemic ± hyperinsulinaemic clamp was similar in all groups (data not shown). In experiment 1, there was a small, non-signi®cant numerical rise in the glucose infusion rates in LG 100268-and LG 100324-treated groups ( Figure 6 ). In rats given BRL 49653, signi®-cantly higher (P`0.05) glucose infusion rates were required to maintain blood glucose at 6 mM compared with control rats. BRL 49653 also signi®cantly increased glucose uptake in diaphragm (P`0.01), gastrocnemius and back muscle (P`0.05), whereas the rexinoids produced no signi®cant effect on glucose uptake (Figure 7) .
In experiment 2, there were no signi®cant differences in steady-state glucose infusion rates and tissue glucose utilization between control and treated groups (data not shown), but the insulin concentration in all the treated rats was approximately half that of controls despite the fact that a similar insulin infusion rate was used in all the animals.
Discussion
Previous studies have shown that chronic treatment of obaob mice with rexinoids can decrease glucose and insulin concentrations and ameliorate insulin resistance without affecting food intake and body weight. 7 In the present study, we examined the effects of chronic treatment with the rexinoids LG 100268 and LG 100324 on the metabolic status of obese Zucker rats, a model of morbid obesity and insulin resistance, and compared the effects of rexinoids with that of the thiazolidinedione BRL 49653.
Two separate experiments were conducted using faafa rats from different suppliers. Although the two sets of rats had been derived ultimately from the original stock of Zucker and Zucker (1961), 14 there were clear differences in the genetic background. Thus, the coat colour of rats from Charles River was brown, whereas the rats from St George's Hospital, London had coat colouring similar to that of the original rats. As has been described in mouse strains expressing the obaob gene, 15 the background strain clearly affects the phenotype. Thus, rats from St 
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George's Hospital were heavier and much more hyperinsulinaemic than rats from Charles River. The overall results from the two experiments suggest that the effects of rexinoids and BRL 49653 may depend on the degree of obesity and severity of the hyperinsulinaemia and insulin resistance.
Unlike the studies in obaob mice, 7 chronic treatment of obese Zucker rats with LG 100268 and LG 100324 decreased signi®cantly daily food intake, with the effect being more profound during the second week of dosing than in the ®rst week. It seems likely that this reduction in food intake is responsible for the reduced weight gain in rexinoid-treated animals. The mechanisms by which the rexinoids inhibit food intake are not known. However, it is unlikely that this effect is mediated through the leptin pathway since the Zucker faafa rats have a mutation in the leptin receptor (a single-base substitution results in an amino acid change affecting dimerization of the receptor). 16 Furthermore, LG 100268 has been shown to reduce plasma leptin levels in obese Zucker rats due to either a direct effect on leptin transcription andaor the reduction in fat mass. 17 Whether LG 100268 and LG 100324 affect the neuropeptide Y (NPY) pathway and other satietyassociated factors remains to be investigated. Despite the decreased food intake and restrained body weight gain, all animals in these treatment groups behaved normally. In contrast to the rexinoids, the daily food intake in BRL 49653-treated animals was signi®cantly increased in the present study (experiment 1). Such an effect has also been observed in other studies with BRL 49653 18, 19 and other thiazolidinediones, such as MCC-555, 20 suggesting that this phenomenon is a general property of these compounds and it has been shown to be independent of leptin and NPY. 19 Treatment with the rexinoids resulted in a trend towards a lowering of the blood glucose concentration in ad-lib fed rats by almost 1 mmolal. Although this was not signi®cant, it occurred at the same time that insulin concentrations were decreased by more than 80% (Figure 4 ). These changes were most evident in experiment 2, which used the more hyperinsulinaemic, insulin resistant rats. Figure 8 shows the scattergram plot of the blood glucoseaplasma insulin ratios for each rat. Both rexinoids produced a signi®cant change in the ratio after 2 weeks of treatment, whereas BRL 49653 had no signi®cant effect. 
The 5 h-fasted plasma insulin concentrations (taken at the end of the treatment period and prior to the euglycaemic clamp) were also signi®cantly reduced by LG 100268 and LG 100324, whereas there was only a trend towards a decrease in rats given BRL 49653. Previous studies with thiazolidinediones have shown different results regarding effects on plasma insulin. Some thiazolidinediones have been reported to reduce plasma insulin concentrations in Zucker diabetic fatty rats and obese Zucker rats, 21 ± 23 whereas other workers found no effect on plasma glucose and insulin concentrations following pioglitazone treatment in those animal models. 24 The insulin infusion rate used in the hyperinsulinaemic clamp in the present study was 10 mUakgamin, which was designed to raise plasma insulin level signi®cantly and thereby stimulate glucose disposal but not such as to completely suppress hepatic glucose output. The plasma insulin concentration achieved in the control group during the euglycaemic ± hyperinsulinaemic clamp is consistent with those obtained in previous studies. 25 However, the insulin concentrations achieved during the clamp in both rexinoid-and BRL 49653-treated groups were only about 49 ± 57% of the control values (experiment 2). The observed lower insulin levels in the treated groups during the clamp is probably due to an increase in the rate of insulin clearance. By using a two-step insulin clamp (insulin at 2 and 10 mUakgamin), Bowen et al 26 have demonstrated that CP 68,722, a thiazolidinedione derivative, reduced plasma insulin levels markedly to about 50% of the levels found in the untreated animals during the 10 mUakgamin insulin infusion. Increased insulin clearance in liver and kidney (and possibly insulin target organs) could account for the observed lower levels of insulin during the clamp in the present study, but it is not known whether this effect is associated with the effect of the drugs on insulin sensitivity. The lower plasma insulin concentrations during the clamp in the rexinoid and BRL 49653-treated animals obscures conclusions that can be drawn from the clamp study. Nevertheless, the same rate of glucose disposal achieved in all treatment groups at much lower insulin levels (about 50% of the control value) clearly indicates the enhanced insulin sensitivity following rexinoid-and BRL 49653-treatment.
A surprising ®nding in the present study was the major difference in insulin sensitivity in faafa rats from two different sources. It indicates that both the genetic mutation and the overall genetic background affect the phenotype. This phenotypic difference altered the response to the compounds that were obtained in the euglycaemic ± hyperinsulinaemic clamp study. Nevertheless, both studies indicated that insulin sensitivity was improved, although with the rexinoids the major action seemed to be to reduce the insulin concentration rather than stimulate glucose uptake.
In summary, 2-week chronic treatment of obese Zucker rats with LG 100268 and LG 100324 reduced daily food intake and body weight gain. These rexinoids are more potent in lowering blood glucose and plasma insulin concentrations than BRL 49653. Irrespective of the mechanisms, results from the present study provide indirect evidence of increased insulin sensitivity following the treatment with LG 100268 and LG 100324. The combination of RXR and PPARg ligands has been shown to have additive or synergistic effects in stimulating transcription and reducing the degree of hyperglycaemia in animal models of NIDDM. 7 The additional potential of rexinoids to cause weight loss suggests that either rexinoids alone, or in combination with thiazolidinedione, may provide a new approach to the treatment of insulin resistance and NIDDM.
